Comparison of clinical efficacy of oxcarbazepine and lamotrigine combined with escitalopram, and impact on prognostic quality of life in treating patients with epilepsy and depressive disorder

Zhang,Xiaoguang; Zhao,Wenli

doi:10.3892/etm.2020.9275

Comparison of clinical efficacy of oxcarbazepine and lamotrigine combined with escitalopram, and impact on prognostic quality of life in treating patients with epilepsy and depressive disorder

Authors:
- Xiaoguang Zhang
- Wenli Zhao
View Affiliations

Affiliations: Center of Brain Diseases, Sunshine Union Hospital, Weifang, Shandong 261061, P.R. China, Department of Neurosurgery, Weifang No. 2 People's Hospital, Weifang, Shandong 261041, P.R. China
Published online on: October 5, 2020 https://doi.org/10.3892/etm.2020.9275
Article Number: 146

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study aimed to investigate the clinical efficacy of oxcarbazepine and lamotrigine combined with escitalopram in treating patients with epilepsy and depressive disorder, and their influence on the prognostic quality of life. A total of 108 patients with epilepsy and depression were selected as research participants. Among them, 53 patients were treated by oxcarbazepine combined with escitalopram (group A) and 55 patients were treated by lamotrigine combined with escitalopram (group B). Following six‑month treatment, efficacy, epilepsy frequency and duration, Hamilton Depression Rating (HAMD) and Montgomery‑Asberg Depression Rating (MADRS) scores, adverse reactions, improvement of electroencephalogram (EEG) epileptic discharge, quality of life, 1‑year drug retention rate and withdrawal reasons of the two groups were compared. There was no remarkable difference in the total efficacy rate between both groups. The number and duration of epileptic seizures, improvement of EEG epileptic discharge and quality of life in the two groups significantly improved after treatment, with no marked difference. HAMD and MADRS scores of patients from group B were significantly lower after treatment compared with those of patients from group A. The incidence rate of adverse reactions in group B was dramatically lower compared with group A, and the 1‑year drug retention rate of group B was dramatically higher compared with that in group A. Both oxcarbazepine and lamotrigine combined with escitalopram exhibited good efficacy in patients with epilepsy and depressive disorder, and they may effectively improve the prognostic quality of life of patients. Lamotrigine combined with escitalopram presented with a better antidepressant effect and safety, with higher patient tolerance.

View Figures

View References

1	Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, Abou-Khalil B, Burakgazi-Dalkilic E, Llanas Park E, Stern J, et al: Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 92:82–90. 2018.PubMed/NCBI View Article : Google Scholar
2	Chen Z, Brodie MJ, Liew D and Kwan P: Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: A 30-year longitudinal cohort study. JAMA Neurol. 75:279–286. 2018.PubMed/NCBI View Article : Google Scholar
3	Cooper YA, Pianka ST, Alotaibi NM, Babayan D, Salavati B, Weil AG, Ibrahim GM, Wang AC and Fallah A: Repetitive transcranial magnetic stimulation for the treatment of drug-resistant epilepsy: A systematic review and individual participant data meta-analysis of real-world evidence. Epilepsia Open. 3:55–65. 2017.PubMed/NCBI View Article : Google Scholar
4	Beamer E, Fischer W and Engel T: The ATP-gated P2X7 receptor as a target for the treatment of drug-resistant epilepsy. Front Neurosci. 11(21)2017.PubMed/NCBI View Article : Google Scholar
5	Zhang L, Wang C and Li W: A meta-analysis of randomized controlled trials on levetiracetam in the treatment of pediatric patients with epilepsy. Neuropsychiatr Dis Treat. 14:769–779. 2018.PubMed/NCBI View Article : Google Scholar
6	Liu JT, Liu B and Zhang H: Surgical versus medical treatment of drug-resistant epilepsy: A systematic review and meta-analysis. Epilepsy Behav. 82:179–188. 2018.PubMed/NCBI View Article : Google Scholar
7	Yun JH: Comparison of lamotrigine and oxcarbazepine monotherapy for pediatric focal epilepsy: An observational study. Seizure. 60:123–126. 2018.PubMed/NCBI View Article : Google Scholar
8	Tombini M, Pellegrino G, Assenza G and Lazzaro VD: De novo multifocal myoclonus induced by lamotrigine in a temporal lobe epilepsy case. J Neurol Sci. 373:31–32. 2017.PubMed/NCBI View Article : Google Scholar
9	Singh T, Kaur T and Goel RK: Adjuvant quercetin therapy for combined treatment of epilepsy and comorbid depression. Neurochem Int. 104:27–33. 2017.PubMed/NCBI View Article : Google Scholar
10	Luszczki JJ, Wlaz A, Karwan S, Florek-Luszczki M and Czuczwar SJ: Effects of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures in mice. Eur J Pharmacol. 720:247–254. 2013.PubMed/NCBI View Article : Google Scholar
11	Thelengana A, Shukla G, Srivastava A, Singh MB, Gupta A, Rajan R, Vibha D, Pandit AK and Prasad K: Cognitive, behavioural and sleep-related adverse effects on introduction of levetiracetam versus oxcarbazepine for epilepsy. Epilepsy Res. 150:58–65. 2019.PubMed/NCBI View Article : Google Scholar
12	Gorman JM, Korotzer A and Su G: Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: Pooled analysis of placebo-controlled trials. CNS Spectr. 7 (Suppl 1):40–44. 2002.PubMed/NCBI View Article : Google Scholar
13	Gill SJ, Lukmanji S, Fiest KM, Patten SB, Wiebe S and Jetté N: Depression screening tools in persons with epilepsy: A systematic review of validated tools. Epilepsia. 58:695–705. 2017.PubMed/NCBI View Article : Google Scholar
14	Carneiro AM, Fernandes F and Moreno RA: Hamilton depression rating scale and montgomery-asberg depression rating scale in depressed and bipolar I patients: psychometric properties in a Brazilian sample. Health Qual Life Outcomes. 13(42)2015.PubMed/NCBI View Article : Google Scholar
15	Wijnen BF, Mosweu I, Majoie MH, Ridsdale L, de Kinderen RJ, Evers SM and McCrone P: A comparison of the responsiveness of EQ-5D-5L and the QOLIE-31P and mapping of QOLIE-31P to EQ-5D-5L in epilepsy. Eur J Health Econ. 19:861–870. 2018.PubMed/NCBI View Article : Google Scholar
16	Peng WF, Fan F, Li X, Zhang QQ, Ding J and Wang X: Different behavioral and pathological changes between epilepsy-associated depression and primary depression models. Epilepsy Behav. 83:212–218. 2018.PubMed/NCBI View Article : Google Scholar
17	Rider FK, Danilenko OA, Grishkina MN, Kustov GV, Akzhigitov RG, Lebedeva AV and Gekht AB: Depression and epilepsy: Comorbidity, pathogenetic similarity, and principles of treatment. Neurosci Behav Physiol. 48:78–82. 2018.
18	Josephson CB, Lowerison M, Vallerand I, Sajobi TT, Patten S, Jette N and Wiebe S: Association of depression and treated depression with epilepsy and seizure outcomes: A multicohort analysis. JAMA Neurol. 74:533–539. 2017.PubMed/NCBI View Article : Google Scholar
19	Mula M: Depression in epilepsy. Curr Opin Neurol. 30:180–186. 2017.PubMed/NCBI View Article : Google Scholar
20	Johannessen Landmark C, Baftiu A, Tysse I, Valsø B, Larsson PG, Rytter E and Johannessen SI: Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: A comparison of the impact of age and comedication. Ther Drug Monit. 34:440–445. 2012.PubMed/NCBI View Article : Google Scholar
21	Glauser TA: Oxcarbazepine in the treatment of epilepsy. Pharmacother J Hum Pharmacol Drug Ther. 21:904–919. 2012.
22	D'Anto J, Wnuk W, Rossetti AO, Decosterd LA, Buclin T and Novy J: Lamotrigine serum levels: Ceiling effect in people with epilepsy in remission? Epilepsy Behav. 74:41–44. 2017.PubMed/NCBI View Article : Google Scholar
23	Zhang M, Ming LI, Zhang X, et al: The clinical efficacy of lamotrigine in the treatment of epilepsy with depression and the influence on cognitive function. Chinese Journal of Medicinal Guide, 2017.
24	Martinović Z, Buder N, Milovanović M and Velićković R: Antiepileptic, behavioral, and antidepressant effects of adjuvant lamotrigine therapy in drug-resistant epilepsy. Vojnosanit Pregl. 61:485–490. 2004.PubMed/NCBI View Article : Google Scholar
25	Azorin JM, Llorca PM, Despiegel N and Verpillat P: Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder. Encephale. 30:158–166. 2004.PubMed/NCBI View Article : Google Scholar
26	Kutluay E, McCague K, D'Souza J and Beydoun A: Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav. 4:175–180. 2003.PubMed/NCBI View Article : Google Scholar
27	Sunwoo JS, Park BS, Ahn SJ, Hwang S, Park CY, Jun JS, Kim DW, Lee ST, Jung KH, Park KI, et al: Three-year retention rates of levetiracetam, topiramate, and oxcarbazepine: A retrospective Hospital-based Study. Clin Neuropharmacol. 40:56–62. 2017.PubMed/NCBI View Article : Google Scholar
28	Reilly C, Atkinson P, Das KB, Chin RF, Aylett SE, Burch V, Gillberg C, Scott RC and Neville BG: Neurobehavioral comorbidities in children with active epilepsy: A population-based study. Pediatrics. 133:e1586–e1593. 2014.PubMed/NCBI View Article : Google Scholar